Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$2.15 CAD
Change Today 0.00 / 0.00%
Volume 38.2K
As of 12:27 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

resverlogix corp (RVX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - C$3.14
52 Week Low
12/11/14 - C$0.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESVERLOGIX CORP (RVX)

Related News

No related news articles were found.

resverlogix corp (RVX) Related Businessweek News

No Related Businessweek News Found

resverlogix corp (RVX) Details

Resverlogix Corp., a clinical stage biotechnology company, develops small molecules that selectively inhibit Bromodomain and ExtraTerminal domain proteins for high risk vascular diseases. The company is developing RVX-208, a small molecule that is in clinical trials for the treatment of atherosclerosis and other chronic diseases, such as diabetes mellitus and Alzheimer's disease. Resverlogix Corp. is headquartered in Calgary, Canada.

19 Employees
Last Reported Date: 07/29/14

resverlogix corp (RVX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$404.6K
Chief Financial Officer
Total Annual Compensation: C$241.7K
Senior Vice President of Medical Affairs
Total Annual Compensation: C$183.8K
Compensation as of Fiscal Year 2014.

resverlogix corp (RVX) Key Developments

Resverlogix In Discussions To Be Acquired

"We are in discussions with multiple companies, not just one," Donald McCaffrey, Chief Executive Officer of Resverlogix Corp. (TSX:RVX) said. Resverlogix is in discussion with several global pharmaceutical companies for a potential sale.

Resverlogix Enters into Licensing Agreement with Shenzhen Hepalink Pharmaceutical

Resverlogix has entered into licensing agreement with Shenzhen Hepalink Pharmaceutical. As per the agreement, RVX will grant Shenzhen Hepalink rights to its RVX-208 for all indications. RVX, in return, will receive sales-based milestone payments from Hepalink, each ranging from USD 5 million to USD 90 million. It will also be entitled to royalties based on net sales.

Resverlogix Corp. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 01:45 PM

Resverlogix Corp. Presents at ChinaBio Partnering Forum 2015, Apr-15-2015 01:45 PM. Venue: Kerry Hotel, Pudong, Shanghai, China.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVX:CN C$2.15 CAD 0.00

RVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RVX Industry Range
Price/Earnings 74.8x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 76.4x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESVERLOGIX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at